Keros Therapeutics Faces Setback as Lung Drug Trial Dosing is Halted

In a significant blow to Keros Therapeutics, the company announced a temporary halt in dosing during a clinical trial for its experimental lung drug. This decision comes after preliminary safety concerns arose, leading to a rapid decline in the company’s stock value.

Continue reading